Antioxidant therapeutics in parkinson’s disease: Current challenges and opportunities

61Citations
Citations of this article
115Readers
Mendeley users who have this article in their library.

Abstract

Oxidative stress is considered one of the pathological mechanisms that cause Parkinson’s disease (PD), which has led to the investigation of several antioxidants molecules as a potential therapeutic treatment against the disease. Although preclinical studies have demonstrated the efficacy of these compounds to maintain neuronal survival and activity in PD models, these results have not been reflected in clinical trials, antioxidants have not been able to act as disease modifiers in terms of clinical symptoms. Translational medicine currently faces the challenge of redesigning clinical trials to standardize criteria when testing molecules to reduce responses’ variability. Herein, we discuss current challenges and opportunities regarding several non-enzymatic antioxidants’ therapeutic molecules for PD patients’ potential treatment.

Cite

CITATION STYLE

APA

Duarte-Jurado, A. P., Gopar-Cuevas, Y., Saucedo-Cardenas, O., Loera-Arias, M. de J., Montes-De-oca-luna, R., Garcia-Garcia, A., & Rodriguez-Rocha, H. (2021, March 1). Antioxidant therapeutics in parkinson’s disease: Current challenges and opportunities. Antioxidants. MDPI. https://doi.org/10.3390/antiox10030453

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free